Actinium Pharmaceuticals, Inc.

342 articles about Actinium Pharmaceuticals, Inc.

• Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

  9/7/2023

  Actinium Pharmaceuticals, Inc. today highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia (r/r AML) and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting.

• Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

  8/31/2023

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in Houston, September 6-9, 2023. 

• Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

  8/21/2023

  Actinium Pharmaceuticals, Inc. today details two abstracts accepted for oral and poster presentation at the upcoming European Association of Nuclear Medicine (EANM) 2023 Congress, which will be held in Vienna, September 9-13, 2023.

• Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

  7/24/2023

  Actinium Pharmaceuticals, Inc. today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27, 2023.

• SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data

  6/26/2023

  Actinium Pharmaceuticals, Inc. today announced that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting selected Abstract 685 titled "Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia.

• Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

  6/23/2023

  Actinium Pharmaceuticals, Inc. today details the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago.

• Actinium Pharma to Present at the Maxim Healthcare Virtual Conference 2023

  6/16/2023

  Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, announced that the Company will participate in a fireside chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST.

• Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit

  6/14/2023

  Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, announced that the Company will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 1:30 PM EST.

• Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

  6/12/2023

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.

• Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes

  6/7/2023

  Actinium Pharmaceuticals, Inc. announced that it will be added as a member of the small-cap Russell 2000® and all-cap Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19 and effective upon the U.S. market close on June 23, 2023.

• Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers

  5/22/2023

  Actinium Pharmaceuticals, Inc. today announced that six abstracts have been accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago, June 24-27, 2023. 

• Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)

  5/11/2023

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming European Hematology Association 2023 Congress (EHA), which will be held in Frankfurt, Germany June 8-11, 2023. 

• Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day

  5/10/2023

  Actinium Pharmaceuticals, Inc. today announced that the Company's management team will participate in 1x1 meetings and deliver a corporate presentation on Monday, May 15, 2023 at 3:20 PM EST at the Guggenheim Healthcare Talks Radiopharmaceuticals Day.

• Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks

  4/28/2023

  Actinium Pharmaceuticals, Inc. today announced that two posters detailing positive clinical experiences are being presented at the 48th Annual Oncology Nursing Society (ONS) Congress, which is being held on April 26–30, 2023, in San Antonio, Texas.

• Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

  4/27/2023

  Actinium Pharmaceuticals, Inc. today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting that was held in Paris, France April 23 – 26, 2023.

• Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting

  4/19/2023

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida.

• Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting

  4/19/2023

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) announced today the first ever data demonstrating the utility of Actimab-A to depleted myeloid derived suppressor cells (MDSCs), which are ubiquitously present within the solid tumor microenvironment as well as blood cancers.

• Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

  4/3/2023

  Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, reported its financial results for the quarter and year ended December 31, 2022, and provided a corporate update.

• Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting

  3/16/2023

  Actinium Pharmaceuticals, Inc. announced today that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida.

• Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference

  3/15/2023

  Actinium Pharmaceuticals, Inc. today announced that the Company's management team will participate in a virtual presentation at Oppenheimer's 33rd Annual Healthcare Conference being held March 13-17, 2023.